Featured Research

from universities, journals, and other organizations

New Anti-Tumor Drug Promising In Animal Studies, UF Research Shows

Date:
April 7, 2000
Source:
University Of Florida Health Science Center
Summary:
A drug that indirectly attacks tumors by destroying the blood vessels that feed them substantially boosts the effectiveness of traditional anti-cancer medications in laboratory animals, new University of Florida research shows.

GAINESVILLE, Fla. --- A drug that indirectly attacks tumors by destroying the blood vessels that feed them substantially boosts the effectiveness of traditional anti-cancer medications in laboratory animals, new University of Florida research shows.

Scientists found that by combining combretastatin A-4 prodrug with standard chemotherapy agents, tumor cells in mice were killed off at 10 to 500 times the rate of chemotherapy alone.

The drug was employed against human tumor cells - breast, ovarian and AIDS-related Kaposi's sarcoma - that had been injected into the animals.

"We previously had shown that the drug was effective when combined with radiation therapy," said Dietmar Siemann, a professor of radiation oncology in UF's College of Medicine. "But now we have shown that it performs well with traditional anti-cancer drugs. It does well on its own, but it's also a way to enhance the effectiveness of chemotherapy."

Siemann and his colleagues presented their findings earlier this week at the American Association for Cancer Research meeting in San Francisco. He was joined by UF graduate student Lingyun Li and pathologist Amyn Rojiani of the University of South Florida.

Combretastatin, a small organic molecule first identified in the bark of the African bush willow, is part of a new class of compounds that target a tumor's vascular system. The drug differs from the "anti-angiogenesis" medications that have received a lot of attention in that it attacks existing and growing tumor vessels rather than preventing the formation of new ones.

Earlier research by Siemann was supported in part by OXiGENE Inc., the developer of combretastatin. The Boston- and Sweden-based biopharmaceutical company finalized an agreement in December to transfer the cancer therapy development rights for the drug to Bristol-Myers Squibb Co.

Combretastatin currently is being tested in Phase 1 trials of patients with advanced cancers. Siemann anticipates that the drug will move onto larger Phase 2 studies within the next few months. In general, small Phase 1 and Phase 2 trials are designed to determine preliminary safety and effectiveness issues. If results are positive, the drug is then tested in a larger, final clinical study that sometimes involves thousands of patients.

Siemann said he wanted to explore the use of combretastatin in Kaposi's sarcoma, the most common kind of tumor in AIDS patients, because there aren't many good treatments available.

"Kaposi's sarcoma is also a highly vascularized tumor, so it makes sense to try agents that target the vessel system at the disease site," said Siemann, who recently received a $1.4 million grant from the National Institutes of Health to continue his research on vascular-targeting agents.

Because the immune system of people with AIDS is sometimes greatly compromised, they often can receive just a limited amount of standard chemotherapy.

"We found that even by itself, combretastatin is very effective in this model of Kasposi's sarcoma," Siemann said, noting that after an injection, viable tumor cells existed only at the periphery.

When it was combined with drugs typically prescribed for Kaposi's sarcoma -- cisplatin or vinblastine -- tumor cell survival in Kaposi's sarcoma was just one-tenth of that seen with any of the drugs alone. Researchers measured tumor cell survival a day after the medications were injected.

In breast and ovarian tumors models, combretastatin with cisplatin or cyclophosphamide caused a dramatic increase in tumor cell death - a 10- to 500-fold increase-- over any of the medications by themselves.

Combretastatin by itself does not eradicate an entire tumor because it attacks only new blood vessels that have developed to support the cluster of cancerous cells. The outer rim survives because it is nourished by blood vessels that supply normal tissue.

"That's why we use it in combination with other chemotherapy," Siemann said. "That's also very positive, because normal tissue is preserved."

"Combretastatin has great promise," said Amato Giaccia, an associate professor of radiation oncology at the Stanford University School of Medicine. "It ranks at least as well as the other anti-angiogenic compounds in clinical trials."

Giaccia noted that several laboratories around the world are finding similar results with combretastatin and a variety of tumor types. That's encouraging, he said, because "it's getting real and reproducible effects."

"One always needs to interpret animal models cautiously," he continued. "But on the other hand, if you can't cure a tumor in an animal first, your chances of curing a human tumor later are greatly diminished."


Story Source:

The above story is based on materials provided by University Of Florida Health Science Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Florida Health Science Center. "New Anti-Tumor Drug Promising In Animal Studies, UF Research Shows." ScienceDaily. ScienceDaily, 7 April 2000. <www.sciencedaily.com/releases/2000/04/000406114503.htm>.
University Of Florida Health Science Center. (2000, April 7). New Anti-Tumor Drug Promising In Animal Studies, UF Research Shows. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2000/04/000406114503.htm
University Of Florida Health Science Center. "New Anti-Tumor Drug Promising In Animal Studies, UF Research Shows." ScienceDaily. www.sciencedaily.com/releases/2000/04/000406114503.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
'Cadaver Dog' Sniffs out Human Remains

'Cadaver Dog' Sniffs out Human Remains

AP (Oct. 21, 2014) Where's a body buried? Buster's nose can often tell you. He's a cadaver dog, specially trained to find human remains and increasingly being used by law enforcement and accepted in courts. These dogs are helping solve even decades-old mysteries. (Oct. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins